Skip to main navigation menu Skip to main content Skip to site footer
Revista Científica do Hospital e Maternidade José Martiniano de Alencar

Artigo Original

Vol. 3 No. 2 (2022)

Pharmacological treatment for obesity in Brazil: available drugs, efficacy, and associated costs

DOI
https://doi.org/10.54257/2965-0585.v3.i2.56
Submitted
May 26, 2023
Published
2023-07-06

Abstract

Obesity is a chronic medical condition that affects millions of people worldwide. It is characterized by excessive accumulation of body fat, which can lead to a range of health problems, including type 2 diabetes, heart disease, and other chronic conditions. The current medical literature provides an extensive arsenal of clinical therapeutic options for the pharmacological treatment of obesity, which unfortunately is underutilized by most physicians treating obese patients in various settings. In this article, we provide an overview of available drugs, their costs, and efficacy in major clinical studies.

References

  1. Yael M, Marcie P, Sangeeta RK. Antiobesity drug therapy: An individualized and comprehensive approach. Cleveland Clinic Journal of Medicine. 2021;88(8):440.
  2. Nilson EAF, Andrade R, de Brito DA, de Oliveira ML. [Costs attributable to obesity, hypertension, and diabetes in the Unified Health System, Brazil, 2018Costos atribuibles a la obesidad, la hipertensión y la diabetes en el Sistema Único de Salud de Brasil, 2018]. Rev Panam Salud Publica. 2020;44:e32.
  3. Ferrari G, Giannichi B, Resende B, Paiva L, Rocha R, Falbel F, et al. The economic burden of overweight and obesity in Brazil: perspectives for the Brazilian Unified Health System. Public Health. 2022;207:82-7.
  4. Suran M. As Ozempic’s Popularity Soars, Here’s What to Know About Semaglutide and Weight Loss. JAMA. 2023.
  5. Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. Diretrizes brasileiras de obesidade 2016 / ABESO - Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica. – 4.ed. - São Paulo, SP.
  6. Yanovski SZ, Yanovski JA. Progress in Pharmacotherapy for Obesity. JAMA.2021;326(2):129-30.
  7. Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a Disease: The Obesity Society 2018 Position Statement. Obesity. 2019;27(1):7-9.
  8. BRASIL. Agência Nacional de Vigilância Sanitária. Ministério da Saúde. VOTO No 204/2022/SEI/DIRE2/ANVISA. 2022. Disponível em: https://www.gov.br/anvisa/pt-br/composicao/diretoria-colegiada/reunioes-da-diretoria/votos-dos-circuitos deliberativos1 /2022/cd-1284-2022-voto.pdf. Acesso em: 15 maio 2023.
  9. Chanoine J-P, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of Orlistat on Weight and Body Composition in Obese AdolescentsA Randomized Controlled Trial. JAMA. 2005;293(23):2873-83.
  10. Arterburn DE, Crane PK, Veenstra DL. The Efficacy and Safety of Sibutramine for Weight Loss: A Systematic Review. Archives of Internal Medicine. 2004;164(9):994-1003.
  11. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015;373(1):11-22.
  12. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016;315(10):990-1004.
  13. Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother. 2013;47(3):340-9.
  14. COGHILL, David R.; CABALLERO, Beatriz; SOROOSHIAN, Shaw; CIVIL, Richard. A Systematic Review of the Safety of Lisdexamfetamine Dimesylate. Cns Drugs, [S.L.], v. 28, n. 6, p. 497-511, 1 maio 2014. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s40263-014-0166-2.
  15. SCHNEIDER, Elizabeth; HIGGS, Suzanne; DOURISH, Colin T.. Lisdexamfetamine and binge-eating disorder: a systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder. European Neuropsychopharmacology, [S.L.], v. 53, p. 49-78, dez. 2021. Elsevier BV. http://dx.doi.org/10.1016/j.euroneuro.2021.08.001.
  16. ZAROS, K.J.B. (Paraná). Conselho Regional de Farmácia do Paraná. O USO OFF LABEL DE MEDICAMENTOS PARA OBESIDADE. 2018. Disponível em: https://www.crfpr.org.br/uploads/revista/33657/CeW0qho1ZWuSJg2f4Ioml1hrF99F2Etv.pdf. Acesso em: 14 maio 2023.
  17. Pratama KG, Tandarto K, Hengky A. WEIGHT LOSS EFFECT OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN PATIENTS WITH OBESITY WITHOUT DIABETES: A SYSTEMATIC REVIEW. Acta Endocrinol (Buchar). 2022;18(2):216-24.
  18. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27-31.
  19. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
  20. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2018;380(4):347-57.

Most read articles by the same author(s)